chartexchange

FDA agrees ENABLE-2 Phase III trial design for Enliven’s relcobatinib

Clinical Trials Arena | Oct 7, 2026 5:43 AM EDT

Enliven Therapeutics has reached an agreement with the US FDA regarding the final protocol for the ENABLE-2 pivotal Phase III clinical trial evaluating relcobatinib in adults with CML.
The post FDA agrees ENABLE-2 Phase III trial design for Enliven’s relcobatinib appeared first on Clinical Trials Arena .

Read original article